Evidence map›Paper›PMID 20625551›Full record

ArticlePLoS neglected tropical diseases2010

Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin.

Nandy C López, Carolina Valck, Galia Ramírez, Margarita Rodríguez, Carolina Ribeiro, Juana Orellana, Ismael Maldonado, Adriana Albini, Daniel Anacona, David Lemus and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Bugs as drugs: parasite biomolecules as novel therapeutics against breast cancer.American journal of physiology. Cell physiology · 2026
    Review
  4. Review
  5. Article
  6. Parasites revive hope for cancer therapy.European journal of medical research · 2024
    Review
  7. Review
  8. Tumor-Suppressive Cross-Linking of Anti-International journal of molecular sciences · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Frontiers in cell and developmental biology · 2023
    Review
  13. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.Frontiers in cellular and infection microbiology · 2023
    Review
  14. The many faces of parasite calreticulin.Frontiers in immunology · 2023
    Review
  15. Comorbidities involving parasitic diseases: A look at the benefits and complications.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  16. Anti-Tumor Effect of Parasitic Protozoans.Bioengineering (Basel, Switzerland) · 2022
    Review
  17. Frontiers in cell and developmental biology · 2022
    Article
  18. Is It Possible to Intervene in the Capacity ofFrontiers in immunology · 2021
    Review
  19. Review
  20. The Recombinant Protein Based onFrontiers in cell and developmental biology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Nandy C LópezInstitute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Carolina Valck
Galia Ramírez
Margarita Rodríguez
Carolina Ribeiro
Juana Orellana
Ismael Maldonado
Adriana Albini
Daniel Anacona
David Lemus
Lorena Aguilar
Wilhelm Schwaeble
Arturo Ferreira
University of Chile · CLMultiMedica · ITUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Latin America, 18 million people are infected with Trypanosoma cruzi, the agent of Chagas' disease, with the greatest economic burden. Vertebrate calreticulins (CRT) are multifunctional, intra- and extracellular proteins. In the endoplasmic reticulum (ER) they bind calcium and act as chaperones. Since human CRT (HuCRT) is antiangiogenic and suppresses tumor growth, the presence of these functions in the parasite orthologue may have consequences in the host/parasite interaction. Previously, we have cloned and expressed T. cruzi calreticulin (TcCRT) and shown that TcCRT, translocated from the ER to the area of trypomastigote flagellum emergence, promotes infectivity, inactivates the complement system and inhibits angiogenesis in the chorioallantoid chicken egg membrane. Most likely, derived from these properties, TcCRT displays in vivo inhibitory effects against an experimental mammary tumor. METHODOLOGY AND PRINCIPAL

findingsTcCRT (or its N-terminal vasostatin-like domain, N-TcCRT) a) Abrogates capillary growth in the ex vivo rat aortic ring assay, b) Inhibits capillary morphogenesis in a human umbilical vein endothelial cell (HUVEC) assay, c) Inhibits migration and proliferation of HUVECs and the human endothelial cell line Eahy926. In these assays TcCRT was more effective, in molar terms, than HuCRT: d) In confocal microscopy, live HUVECs and EAhy926 cells, are recognized by FITC-TcCRT, followed by its internalization and accumulation around the host cell nuclei, a phenomenon that is abrogated by Fucoidin, a specific scavenger receptor ligand and, e) Inhibits in vivo the growth of the murine mammary TA3 MTXR tumor cell line. CONCLUSIONS/SIGNIFICANCE: We describe herein antiangiogenic and antitumor properties of a parasite chaperone molecule, specifically TcCRT. Perhaps, by virtue of its capacity to inhibit angiogenesis (and the complement system), TcCRT is anti-inflammatory, thus impairing the antiparasite immune response. The TcCRT antiangiogenic effect could also explain, at least partially, the in vivo antitumor effects reported herein and the reports proposing antitumor properties for T. cruzi infection.

Indexed as

Angiogenesis InhibitorsAnimalsAntineoplastic AgentsCalreticulinCells, CulturedEndothelial CellsHumansMammary Neoplasms, ExperimentalMiceOrgan Culture TechniquesRatsRats, Sprague-DawleyTrypanosoma cruziAngiogenesis InhibitorsAntineoplastic AgentsCalreticulin

Identifiers

PMID20625551
PMCPMC2897838
OpenAlexW2129860254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.